The products offered on this website (except supplements) are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
All articles and product information provided on this website is for informational and educational purposes only.
A new pharmaceutical grade synthetic Aphrodisiac; Erectile / Sexual Dysfunction or Impotence in men; Sexual Dysfunction in women (Sexual Arousal Disorder).
Purchase a 30 ml of bacteriostatic water separately. One 30ml bottle will be enough for multiple vials of peptides.
PT-141 is a research peptide also referred to as bremelanotide and sometimes known as the ‘libido drug’. PT-141 is a derivative of M2 (Melanotan 2). However, unlike M2, it lacks the c-terminal amide molecules. Bremelanotide is being studied and promises to control blood flow restriction, inflammation and more importantly help treat sexual dysfunction in both males and females.
During the studying of and experimentation with the tanning peptide, melanotan 2 for melanoma prevention, sexual arousal and spontaneous erections were identified as a side effect in some of the test subjects. Testing was then carried out on human male volunteer subjects with a history of erectile dysfunction and nine of the original ten subjects experienced spontaneous erections when the drug was administered. Further studies revealed that the source of these effects was what is now referred to as PT-141.
It works by activating specific melanocortin receptors MC4-R and MC3-R in the CNS. Through these chemical interactions, PT-141 can influence multiple physiological responses such as appetite and sexual behaviour. Bremelanotide has shown potential in treating sexual dysfunction mainly male erectile dysfunction. Studies also reveal that PT-141 does not have any effect on the vascular system; instead, it allegedly works directly on the melanocortin receptors in the brain hence increasing sexual stimulation in test subjects.
Rigorous research also revealed that due to PT-141’s ability to regulate inflammation and blood flow restriction, PT-141 shows a lot of promise in managing reperfusion injury and the onset of haemorrhagic shock. Basically, bremelanotide could potentially not only reduce but also prevent inflammation triggered by different diseases or irritants which in turn could decrease the damage that occurs in blood vessels and surrounding tissues.